Opioid-induced respiratory depression (OIRD) poses a significant risk for patients with opioid dependencies, often leading to severe respiratory distress and potential fatalities. Current methods for monitoring respiratory function are limited in providing continuous, real-time data necessary for timely intervention. The lack of proactive monitoring solutions contributes to delayed detection and intervention, increasing the risk of adverse events.

PneumoWave offers a solution for real-time respiratory monitoring through a chest-worn biosensor that continuously captures and transmits respiratory data. The sensor wirelessly transmits data to a cloud platform where proprietary algorithms analyze the data to detect potential respiratory adverse events. Healthcare providers are promptly notified through an alert system, enabling timely interventions and personalized treatment adjustments. The integrated platform aims to shift respiratory care towards proactive intervention, reducing the risk of respiratory distress in patients.

Small, chest-worn biosensor for continuous data capture and wireless transmission

Proprietary algorithms for real-time detection of respiratory adverse events

Cloud platform for remote data viewing and personalized treatment

Alert system for prompt notification of potential respiratory distress

Data Collection Mobile (DCM) system for documenting physical movement during sleep and other activities

The primary target audience includes healthcare providers and clinical researchers focused on managing patients at risk of opioid-induced respiratory depression and other respiratory-related conditions.